HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong — Stella

Home/Human Immunodeficiency Virus/

View on ClinicalTrials.gov

Recruiting

Back to Human Immunodeficiency Virus trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Hong Kong

The Chinese University of Hong Kong Phase 1 Clinical Trial Centre at Prince of Wales Hospital, Shatin, New Territories

Key details

Phase

Early testing

Sponsor

Immuno Cure Holding (HK) Limited

Collaborators

Immuno Cure 1 Limited, The University of Hong Kong

Enrollment target

~22 participants

Started

March 2026

Primary completion

March 2027

Age range

18 Years – 60 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.